logo

For the Inventor, By the Inventor

Ambler, PA, United States of America

David C Underwood

This inventor holds 5 USPTO granted patents. Top assignee: Smithkline Beecham Corporation. Active years: 2000-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David C Underwood. Retrieved from https://idiyas.com/inventor/david-c-underwood-m9rbqvbi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5

% Patents Active = 20.0

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:

goldMedal5 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 2000-2006

Loading Chart...
5 patents (USPTO):Explore Patents
1. 7053099 - 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors (2006-05-30),
2. 7053098 - 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors (2006-05-30),
3. 6982270 - 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors (2006-01-03),
4. 6759410 - 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors (2004-07-06),
5. 6121290 - Use of GABA uptake inhibitors as anti-tussive agents (2000-09-19),

Title: Inventor Profile: David C. Underwood

Introduction

David C. Underwood is an accomplished inventor based in Ambler, Pennsylvania. With a significant portfolio of five patents, he has made substantial contributions to the field of pharmaceutical innovations. His work primarily focuses on compounds that serve as inhibitors for specific kinases, showcasing his dedication to advancing therapeutic options.

Latest Patents

Among David's notable patents are two related to 3,4-Dihydro-(1H) quinazolin-2-one compounds, recognized for their potential as CSBP/p38 kinase inhibitors. These novel substituted quinazoline compounds and their compositions can be used in therapeutic contexts, making them a vital part of his innovative contributions to medical science.

Career Highlights

Currently, David C. Underwood is part of the renowned SmithKline Beecham Corporation, where he has contributed to groundbreaking research and development initiatives. His expertise in the pharmaceutical industry is reflected in his ability to create compounds that address significant health challenges.

Collaborations

Throughout his career, David has worked alongside other notable professionals, including Jerry Leroy Adams and Michael J. Bower. Collaborating with such esteemed colleagues has further enriched his research endeavors, leading to advancements in the field of kinase inhibitors.

Conclusion

David C. Underwood's work exemplifies the role of innovation in healthcare. His patents and collaborations underscore his commitment to improving therapeutic strategies through scientific exploration. As he continues his journey within SmithKline Beecham Corporation, the impact of his inventions will likely inspire future advancements in pharmacology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…